Johnson announces $16.6 billion acquisition of Abiomed, a maker of heart equipment

CTOnews.com, Nov. 2-Johnson & Johnson, the world's largest healthcare products company, announced today that it offered to acquire all outstanding shares of Abiomed, a breakthrough heart, lung and kidney support technology company, with an advance payment of $380.00 per share, equivalent to about $16.6 billion (currently about 120.848 billion yuan) in the enterprise value, including the cash acquisition.

Abiomed shareholders will also be given non-tradable contingent valuable rights (CVR), and holders will be entitled to cash of up to $35.00 per share if certain commercial and clinical milestones are achieved. The deal was unanimously approved by the boards of directors of both companies.

CTOnews.com learned that Johnson said the deal expanded Johnson Medical Technology (JJMT) as a growing cardiovascular innovator and raised the standard of care for one of the biggest unmet needs in the health care sector: heart failure and rehabilitation. Cardiovascular disease is the leading cause of death, and all forms of cardiovascular disease can lead to heart failure, which is a huge cost to the health system due to prolonged hospitalization and hospitalization.

According to reports, Abiomed is the leading cardiovascular medical technology, the first provider to enter the market, with the first coronary artery disease and heart failure treatment product portfolio, a wide range of life-saving technology innovation channels, and 18 years of profit growth record. Abiomed operates in one of the fastest growing areas of medical technology and has significant expansion opportunities in terms of indications, geography and products.